Catalog # |
Size |
Price |
|
---|---|---|---|
EK-028-14 | 96 wells | $537 |
View/Download (PDF) - for reference only | |||||||||||||||||||||
| Suggested Procedure | ||||||||||||||||||||
Measured values represent approximate 'normal' levels in sample, but do not signify the only possible sample levels. Various factors (e.g. sample storage, assay procedure) can affect results. | Human Plasma: 0.31 ng/ml Human Serum: 0.21 ng/ml | ||||||||||||||||||||
| Recommended | ||||||||||||||||||||
Data may differ slightly based on lot. | 0.16 ng/ml | ||||||||||||||||||||
Data may differ slightly based on lot. | 0.16 - 1.88 ng/ml | ||||||||||||||||||||
| |||||||||||||||||||||
| <10% | ||||||||||||||||||||
| <15% |
The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study.
Francesco Russo et al. BMC Cancer 2013, 13:56 doi:10.1186/1471-2407-13-56
Expression of sweet receptor components in equine small intestine: relevance to intestinal glucose transport.
Kristian Daly et al, AJP - Regu Physiol July 15, 2012 vol. 303 no. 2 R199-R208, doi: 10.?1152/?ajpregu.?00031.?2012
Social Network Confirmation